MedTrace Logo

Memantine Versus Donepezil in Early Stages of Alzheimer's Disease

NCT00505167 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2008-12-29

No results posted yet for this study

Summary

It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.

Conditions

  • Dementia, Alzheimer Type

Interventions

DRUG

Memantine

Patients randomized to receive either memantine or donepezil

DRUG

Donepezil

Patients randomized to receive either memantine or donepezil

Sponsors & Collaborators

  • Clinica Quiron de Zaragoza

    collaborator UNKNOWN

  • Universidad de Zaragoza

    collaborator OTHER

  • Hospital de Barbastro

    collaborator UNKNOWN

  • Hospital Royo Villanova

    collaborator UNKNOWN

  • Hospital Miguel Servet

    lead OTHER

Principal Investigators

  • Pedro J Modrego, MD · Department of Neurology. Hospital Miguel Servet. Zaragoza. Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-07-31
Completion
2008-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505167 on ClinicalTrials.gov